Related by context. All words. (Click for frequent words.) 86 Phase 2b Clinical Trial 85 Meets Primary Endpoint 85 Phase III Trial 84 Phase III Clinical Trial 84 Completes Patient Enrollment 83 Completes Enrollment 83 First Patient Enrolled 83 Phase IIb Clinical Trial 83 NDA Submission 83 Phase 2b Trial 83 Phase IIb Trial 82 Clinical Trial Results 82 Phase 1b Clinical Trial 82 Drug Candidate 82 Pivotal Phase III 82 Receives Orphan Drug Designation 81 Gout Drug 81 Pivotal Trial 81 FDA Accepts 81 Phase 2a Trial 81 Phase 2a Clinical Trial 81 First Patient Treated 81 Migraine Drug 81 Lupus Drug 80 IND Filing 80 Investigational Compound 80 Pivotal Study 80 Submits NDA 80 Milestone Payment 80 Pivotal Phase 80 Initiates Phase III 80 Initiates Phase II 80 Epilepsy Drug 80 Pivotal Clinical Trial 80 Mylan Receives Approval 80 Drug Fails 80 Files IND 80 Improves Survival 80 Generic Version 80 Advanced Melanoma 80 FDA Approvals 79 Arthritis Drug 79 Lung Cancer Drug 79 Initiates Clinical Trial 79 Presents Positive 79 Osteoporosis Drug 79 Demonstrates Positive 79 Initiates Enrollment 79 Expanded Indication 79 Cholesterol Lowering Drug 79 Initiate Phase III 79 Preclinical Data 78 Study Showed 78 Phase III Trials 78 Single Dose 78 Rheumatoid Arthritis Drug 78 Receives Approvable Letter 78 Receives Milestone Payment 78 Achieves Primary Endpoint 78 Initiates Clinical 78 Investigational Treatment 78 Confirmatory Phase 78 Oral Calcitonin 78 Tezampanel 78 Granted Orphan Drug 78 Schizophrenia Drug 78 Prostate Cancer Vaccine 78 Combination REOLYSIN R 78 Adjuvant Treatment 78 FDA Clears 78 Earns Milestone Payment 78 Cholesterol Drug 78 Demonstrates Significant 78 Successfully Completes Phase 77 Trial Evaluating 77 Initiates Clinical Trials 77 Shows Promising 77 Study Evaluating 77 Clinical Trial Data 77 Phase 2b Study 77 Lung Cancer Trial 77 Topline Results 77 Antitumor Activity 77 Blood Pressure Drug 77 Initiate Phase 77 Receives Orphan Drug 77 Patients Treated With 77 Psoriasis Drug 77 Inhaled Insulin 77 Patient Enrolment 77 Pooled Analysis 77 Phase III Pivotal 77 Pivotal Trials 77 Dose Escalation 77 Investigational Agent 76 Oral Fingolimod 76 Vicriviroc 76 Novel Antibiotic 76 Present Preclinical Data 76 Announces FDA Clearance 76 First Patient Dosed 76 Begins Dosing 76 Combination Treatment 76 Clinical Trial Evaluating 76 Receives Fast Track 76 PDUFA Date 76 II Clinical Trial 76 Initiate Clinical Trial 76 Prolongs Survival 76 Survival Benefit 76 FDA Okays 76 Resistant Hypertension 76 Patients Enrolled 76 Milestone Payment From 76 Taro Receives 76 JAK Inhibitor 76 HCV Protease Inhibitor 76 Novel Oral 76 Testosterone Gel 76 Kidney Transplant Patients 76 Prostate Cancer Patients 76 Hormone Refractory Prostate Cancer 76 Weight Loss Drug 76 Diamyd Medical Diamyd 76 Presents Preclinical Data 76 Phase IIa Clinical Trial 76 Patients Suffering 76 Previously Treated 75 Fast Track Status 75 Phase Ib Clinical Trial 75 Renal Cell Carcinoma 75 Commences Phase 75 Phase III Clinical Trials 75 Generic Versions 75 Investigational Drug 75 Statistically Significant 75 Submits Biologics License Application 75 Drug Combo 75 Anticancer Activity 75 Improves Outcomes 75 Nicotine Vaccine 75 Metastatic Melanoma 75 Receives FDA Clearance 75 Anti Clotting Drug 75 Initiates Phase 2b 75 Gets FDA Clearance 75 IND Application 75 Clinical Trial Enrollment 75 Sagent Pharmaceuticals Announces 75 Drug Shows Promise 75 Brentuximab Vedotin SGN 75 Fungal Infections 75 Relapsed Multiple Myeloma 75 Files Investigational 75 Pharmacokinetic Study 75 Key Milestones 75 Immunomedics Announces 75 FDA Clearance 75 Sangamo BioSciences Announces 75 Myeloma Patients 75 Rheumatoid Arthritis Patients 75 Well Tolerated 75 Severe Sepsis 74 Poniard Pharmaceuticals Announces 74 FOLOTYN ® 74 Spectrum Pharmaceuticals Announces 74 Teva Provides Update 74 Pharmacyclics Announces 74 Molecular Diagnostic Test 74 Initiates Phase 74 Announces Tentative Approval 74 Vaccine Adjuvant 74 Positive Opinion 74 Demonstrates Potent 74 Reveals Positive 74 Shows Efficacy 74 Enrolls First 74 Milestone Payments 74 Treated Patients 74 Preclinical Study 74 Improved Survival 74 Systemic Delivery 74 Less Invasive 74 VIVITROL ® 74 Nasdaq Deficiency Notice 74 Significantly Reduced 74 BioElectronics Announces 74 Anti Tumor Activity 74 Therapeutic Competitors Companies 74 Revises FY# Outlook 74 Stem Cell Treatment 74 Significantly Improved 74 Therapeutic Antibody 74 Alvine Pharmaceuticals 74 Lung Cancer Survival 74 Demonstrates Efficacy 74 pralatrexate injection folate analogue 74 Announce License Agreement 74 Osteoporosis Treatment 74 Randomized Phase 74 Heart Failure Patients 74 Drug Prevents 74 Appears Safe 73 Dose Ranging Study 73 Million Milestone Payment 73 Breast Cancer Recurrence 73 Significantly Improves 73 Hypertensive Patients 73 Disease Progression 73 Novel Compound 73 Collaborators Present 73 HER2 Positive Breast Cancer 73 Double Blind Placebo 73 JAK2 Inhibitor 73 Demonstrates Sustained 73 Receives Complete Response 73 Dose Ranging 73 Long Term Efficacy 73 RNAi Therapeutics 73 Anemia Drug 73 Nuvelo Announces 73 Hepatitis C Treatment 73 Elagolix 73 Testosterone Patch 73 Hematological Malignancies 73 Drug Coated Stent 73 Regeneron Pharma 73 Announces Initiation 73 Randomized Clinical Trials 73 Metastatic Colorectal Cancer 73 Receives CE Marking 73 Lupus Nephritis 73 Transdermal Patch 73 Generic Version Of 73 Erectile Dysfunction Drug 73 Study Demonstrates 73 Randomized Clinical Trial 73 Therapeutic Vaccine 73 Telaprevir VX 73 Improve Survival 73 Bone Fracture 73 Chronic Hepatitis C 73 Patients Treated 73 Recurrent Breast Cancer 73 Combo Therapy 73 Desvenlafaxine Succinate 73 Flamel Technologies Announces 73 Cites Positive 73 FDA Panel Recommends 73 MEK Inhibitor 73 Anti Tumor 73 Revises FY# Guidance 73 Subgroup Analysis 73 Treatment Naïve 73 Pulmonary Arterial Hypertension 73 Employment Inducement Awards 73 Vitrasert R 73 TRANSDUR ™ 73 Asthma Treatment 73 AVI BioPharma Announces 73 Protease Inhibitor 73 Optimer Pharma 73 Novel Inhibitor 73 Osteoporosis Drugs 73 NMT Medical Announces 73 Platelet Inhibition 73 Receives Positive Opinion 73 Receive Milestone Payment 73 Drug Maker 73 Enrolling Patients 73 Diabetic Nephropathy 73 Infected Patients 73 Advanced Colorectal Cancer 73 PRN FDA Approves 73 Completes Dosing 73 Colorectal Cancer Patients 73 Abstract Accepted 73 Presents Preclinical 73 Topical Treatment 72 Adjunctive Therapy 72 Licenses Novel 72 Plaque Psoriasis 72 Underwritten Public 72 Minimally Invasive Treatment 72 Renal Cancer 72 Unfractionated Heparin 72 Limb Ischemia 72 EntreMed Presents 72 Intravenous Formulation 72 Anticancer Agent 72 Develop Novel 72 Shows Statistically Significant 72 Phase III Pivotal Trial 72 Treatment Reduces 72 Multiple Myeloma Patients 72 Telik Announces 72 DOR BioPharma Announces 72 Patent Covering 72 Hsp# Inhibitor 72 Demonstrated Significant 72 Anti Inflammatory Drug 72 Generic Lovenox 72 Effectively Treats 72 Resubmission 72 Lifts FY# Outlook 72 Painkiller Abuse 72 NOVAVAX 72 Commence Phase 72 Rotavirus Vaccine 72 Initiates Dosing 72 Adjuvant Chemotherapy 72 Treating Chronic 72 Neoadjuvant Chemotherapy 72 Myelodysplastic Syndromes 72 Blood Thinner 72 Presents Positive Preclinical 72 Patient Accrual 72 Vertex Pharmaceuticals Announces 72 Shingles Vaccine 72 Predict Risk 72 Biomarker Study 72 Nasdaq Delisting Notice 72 Treatment Resistant 72 RNAi Therapeutic 72 Personalized Immunotherapy 72 VIVUS Announces 72 Gene Therapy Trial 72 Supplemental Biologics License Application 72 Fewer Side Effects 72 TriCo Bancshares Announces 72 Ebola Vaccine 72 Acute Heart Failure 72 Prophylactic Treatment 72 Patients Receiving 72 Patient Treated 72 Tumor Growth 72 Significantly Reduces 72 Hormone Receptor Positive 72 Is Well Tolerated 72 Breast Cancer Treatment 72 Antibody Drug Conjugate 72 Randomized Phase II 72 Seasonal Influenza Vaccine 72 Statin Drugs 72 Shows Promise Against 72 Complicated Skin 72 Sapacitabine 72 Oral Mucositis 72 Proven Effective 72 Treatment Naive Patients 72 Eluting Stent 72 Xcytrin R 72 Backs FY# View 72 Clinical Outcome 72 Treatment Shows Promise 72 dependent kinase inhibitor 72 Lung Cancer Patients 72 Smallpox Vaccine 72 Receives Tentative Approval 72 Long Term Survival 72 Slow Progression 72 Anticancer Compound 72 FDA APPROVES 72 Novel Compounds 72 Newly Diagnosed Multiple Myeloma 72 Sustained Reduction 72 Crofelemer budesonide foam 71 Kinase Inhibitor 71 Refractory Hodgkin Lymphoma 71 Metastatic Prostate Cancer 71 Controlled Study 71 Artery Disease 71 Glatiramer Acetate 71 Versus Placebo 71 Premenopausal Women 71 Elderly Patients 71 GATTEX TM 71 Autologous Stem Cell Transplantation 71 Lowers Risk 71 Significant Reduction 71 Chemotherapy Regimen 71 HER2 Positive 71 Medoxomil 71 Randomized Study 71 Inflammatory Disease 71 Diabetic Foot Ulcer 71 Heart Transplant Recipients 71 Acute Attacks 71 Pegloticase 71 Demonstrate Significant 71 ANDA Filing 71 Virus Linked 71 Heartburn Drugs 71 Regenerative Cells 71 Antiviral Drugs 71 Treatment Experienced 71 Patent Issuance 71 Sunesis Pharma 71 Preclinical Models 71 Non Invasive Treatment 71 Investigational Oral 71 Randomized Trials 71 Submits Response 71 Paclitaxel Carboplatin 71 Overactive Bladder 71 Metabolic Disorder 71 Vaccine Candidate 71 Showed Significant 71 XPEL Announces 71 Pre Cancerous 71 Drug Coated Stents 71 MKC# MKC# PP 71 Efficacy Trial 71 Male Contraceptive 71 Drug Resistant 71 Randomized Double Blind 71 Monotherapy 71 Neurocrine Biosciences Announces 71 HDAC Inhibitor 71 Submits Application 71 Kidney Function 71 Data Suggest 71 Mg Usa 71 Gene Variant 71 Node Positive 71 Merge Healthcare Announces 71 Announces Poster Presentations 71 Unsolicited Tender Offer 71 Slows Progression 71 Silicone Breast Implants 71 Monoclonal Antibody 71 Advanced Prostate Cancer 71 Announces Presentation 71 Metastatic Renal Cell Carcinoma 71 Submits Supplemental 71 PPD Declares 71 Chronic Hepatitis B 71 Immunotherapeutic 71 Cholesterol Drugs 71 Lifts FY# Guidance 71 Pivotal Phase II 71 Treat Heart Failure 71 Enlarged Prostate 71 FY# Guidance 71 STERIS Corporation Announces 71 Pediatric Patients 71 Significant Milestones 71 Transplant Patients 71 Prostate Cancer Treatment 71 Anti Nausea 71 Glufosfamide 71 Romiplostim 71 Corautus Genetics 71 Univest Corporation Declares 71 Polymerase Inhibitor 71 Inhaled Nitric Oxide 71 Completes Patient Enrolment 71 Prospective Randomized 71 Aflibercept 71 R lenalidomide 71 Nanophase Announces 71 Anticancer Drug 71 Cutaneous T 71 Cervical Cancer Vaccine 71 Gastric Cancer 71 Reaffirms FY# Outlook 70 Dose Finding 70 Obese Patients 70 Inhaled Corticosteroids 70 Cervical Dysplasia 70 Advanced Renal Cell 70 ST Elevation Myocardial 70 Tyrosine Kinase Inhibitor 70 Pafuramidine 70 Reports Preclinical Data 70 Gene Variation 70 Novel Vaccine 70 Patients Undergoing 70 Treatment Regimen 70 Reduces Pain 70 Miraculins Announces 70 BioSante Pharmaceuticals Announces 70 ORLive Presents 70 Backs FY# Outlook 70 Inc Therapeutic Competitors 70 Newly Diagnosed Patients 70 Demonstrates Potential 70 Acne Drug 70 Patient Outcomes 70 TRANSDUR ® 70 Projected Release Date 70 Reduces Risk 70 Chronic Sinusitis 70 Synta Announces 70 Private Equity Financing 70 Emerging Therapies 70 Malaria Vaccine 70 Vaccine Protects Against 70 Venous Thromboembolism 70 Brain Metastases 70 Disease Modifying 70 Achieves Milestone 70 Significant Improvements 70 Avian Flu Vaccine 70 Receives SFDA Approval 70 Clinical Study 70 Shows Promise 70 Cardiac Resynchronization 70 Knee Osteoarthritis 70 Randomized Double blind 70 Hematological Cancers 70 Schizophrenia Treatment 70 Experimental Vaccine 70 Synthetic Peptide 70 Bazedoxifene 70 Aethlon Medical Releases 70 Oral Laquinimod 70 Indevus Pharma 70 Q1 Loss Narrows 70 Symptom Relief 70 Combination Clinical Trial 70 Embolic Protection 70 Combination Therapy 70 Multicenter Randomized 70 Glaucoma Treatment 70 Phase 2a Study 70 Statin Therapy 70 Biogen Genentech 70 Oral Formulation 70 Increased Mortality 70 Bosutinib 70 Onyx Pharmaceuticals Announces 70 Postmenopausal Women 70 Beta Blocker 70 Ozarelix 70 Novel Protein 70 Gene Mutation 70 Provides Update Regarding 70 Treating Heart Failure 70 Previously Untreated 70 InNexus Biotechnology 70 Diabetic Neuropathic Pain 70 Oncology Compounds 70 Announce Collaboration Agreement 70 Patent Infringement Litigation 70 Clinical Study Shows 70 Mouse Model 70 Cholesterol Lowering 70 FDA Approves Drug 70 Oral Cladribine 70 Insulin Pen 70 Aeolus Pharmaceuticals Announces 70 Potentially Fatal 70 Therapy Reduces 70 Ridaforolimus 70 Backs FY# Forecast 70 Epilepsy Drugs 70 Recombinant Human 70 Small Molecule 70 Transcept Pharmaceuticals 70 Provides Shareholder 70 Genes Predict 70 Reaffirms FY# Guidance 70 Aliskiren 70 Clinically Tested 70 Hip Fractures 70 Crowflight Announces 70 Bone Metastases 70 Bepreve TM 70 Confirms Efficacy 70 Gentium Announces 70 Psoriasis Patients 70 Pirfenidone 70 Sign Licensing Agreement 70 Relapsing Multiple Sclerosis 70 FDA Approves 70 Enhanced Version 70 Ovarian Cancer Patients 70 Systemic Sclerosis 70 novel orally inhaled 70 Successfully Treated 70 Liver Toxicity 70 Minimally Invasive Procedure 70 Aztreonam Lysine 70 Previously Disclosed 70 STELARA TM 70 Diabetic Neuropathy 70 Flagship Product 70 Balloon Angioplasty 70 Cell Transplants 70 Cancer Treatments 70 Nasal Powder 70 Therapeutic Competitors companiesandmarkets.com adEgemonye 70 Novel Mechanism 70 Evaluate Strategic Alternatives 70 ELADUR ™ 70 Drug Eluting Stent 69 Initiate Phase II 69 Therapy Evaluation 69 Genetic Mutation 69 Efficacy Results 69 Benign Prostatic Hyperplasia 69 IL# PE#QQR 69 Nymox NX 69 Begin Clinical Trials 69 Hepatocellular Carcinoma 69 Therapeutic Vaccines 69 Backs FY# Guidance 69 Heart Stents 69 Novel Therapies 69 Nasdaq VNDA 69 Explore Strategic Alternatives 69 Controlled Trial 69 Strengthens Balance Sheet 69 Demonstrates Ability 69 Custirsen 69 Launches Generic Version 69 BioSante Pharmaceuticals Reports 69 Ranolazine 69 See CLINICAL PHARMACOLOGY 69 Study Shows Promise 69 Cyclacel Pharmaceuticals 69 Aneurysm Repair 69 Oral Interferon 69 Diabetic Patients 69 Test Detects 69 Proves Effective 69 IIa Clinical Trial 69 Cardiovascular Prosthetic Devices 69 Soft Tissue Sarcoma 69 Guides FY# Earnings 69 Blast Applications BLAP 69 Study Evaluates 69 Aggressive Prostate Cancer 69 LMI Aerospace Announces 69 Demonstrates Statistically Significant 69 Stent Restenosis 69 Cethromycin 69 GeoMet Announces 69 Drug Eluting Coronary Stent 69 Patent Infringement Suit 69 Telik logo TELINTRA 69 Osteoarthritis Pain 69 Orphan Status 69 Implantable Device 69 Release Capsules 69 Gene Linked 69 Hormone Therapy 69 Adjuvant Therapy 69 Smooth Muscle 69 ELADUR TM 69 VentiRx Pharmaceuticals 69 Companion Diagnostic 69 Nasdaq Notice Regarding 69 Receives NASDAQ 69 Migraine Treatment 69 Bone Marrow Transplants 69 WorldHeart Announces 69 FDA Approvable Letter 69 Bipolar Depression 69 CysDisplay R 69 Stent Implantation 69 Second Pivotal Phase 69 Genetic Variant 69 Namenda Memantine HCl 69 SPRYCEL ® 69 FDA Approval 69 By JAMAAL ABDUL 69 Adenoma 69 Board Authorizes 69 Placebo Controlled Trial 69 Hernia Repair 69 Guidelines Issued 69 Plus Ribavirin 69 Recommends Approval 69 NASDAQ Delisting Notice 69 NASDAQ Listing Requirements 69 Jumps Higher 69 Clinical Evaluation 69 Chronic Myeloid Leukemia 69 Primary Endpoint 69 Therapy Improves 69 Zoledronic Acid 69 Left Ventricular Hypertrophy 69 Significantly Increases 69 TM Drug Eluting 69 Phospholipase A2 69 Osteoarthritis Patients 69 Fondaparinux 69 Submits IND 69 Nasdaq Listing Requirements 69 Bare Metal Stents 69 Peginterferon Alfa 2a 69 NexMed Receives 69 PEGylated Fab fragment 69 Oral Insulin 69 Advanced Ovarian Cancer 69 Multicenter Phase 69 Interferon Beta 69 Identifies Potential 69 XTend Medical XMDC 69 Safinamide 69 Targeted Therapies 69 MBRX 69 Prognostic Significance 69 Radical Prostatectomy 69 Guides FY# FY# 69 Iloperidone 69 Augment TM 69 Guidelines Recommend 69 Voluntary Withdrawal 69 Profitable Third Quarter 69 Annual Meeting Date 69 Stronger Warnings 69 Boosts Survival 69 Reiterates FY# Outlook 69 Newly Identified 69 oral prodrug 69 Dupuytren Contracture 69 Capsules CII 69 Reports Positive 69 Skin Lesions 69 TO AVOID PREGNANCY WHILE 69 Non Dilutive Financing 69 REG1 Anticoagulation System 69 Potent Antiviral Activity 69 Purported Class 69 Generic Protonix 69 Files Patent Application 69 Quarterly Dividend Payment 69 Carotid Stenting 69 Clinical Trial 69 Blood Clot Risk 69 Being Studied 69 Autoimmune Disease 69 Provides Guidance 69 Announce Merger Agreement 69 Insteel Industries Announces 69 Receives Positive 69 Announcement acc 69 Hedgehog Pathway 69 Non Invasive 69 Prostate Tumors 69 Issued Patent 69 Prognostic Value 69 Muscle Function 69 Vaccine Trial 69 Fracture Risk 69 Reacquires 69 Stem Cell Procedure 69 Hypercholesterolemia 69 Lowers FY# Outlook 69 Arthritis Drugs 69 Announces Definitive Agreements 69 Naive Patients 69 ALN HPN 69 Anemia Drugs 69 Study Casts Doubt 69 SulphCo Announces 69 Aloxi ® 69 Chemotherapy Improves 69 Inter Citic Releases 69 Genetic Tests 69 Sinus Infections 69 Anti CD# Antibody 69 Cypher Sirolimus 69 Helps Predict 69 Unsolicited Proposal From 69 EastGroup Properties Announces 69 candidates Azedra 69 Relapsing Remitting Multiple Sclerosis 69 Lung Cancers 69 Vaginal Gel 69 Tremendous Growth 69 Acute Ischemic Stroke 69 Serious Infections 69 Bucindolol 69 Bone Marrow Cells 69 Oral Insulin Capsule 69 Fixed Dose 68 Enteral Feed Devices 68 FY# EPS View 68 Record Third Quarter 68 Maven Semantic 68 Cardiovascular Outcomes 68 Stomach Cancer 68 Sono Tek Announces 68 CYPHER R Sirolimus Eluting 68 Therapeutic Antibodies 68 HCl Injection 68 R MSCRAMM 68 FDA Orphan Drug 68 Immune Cell 68 Endometrial Cancer 68 Study Shows Benefits 68 Successfully Treats 68 Silicone Breast Implant 68 Balance Sheet Restructuring 68 Preterm Labor 68 Successful Completion 68 Cancer Recurrence 68 Tablet Formulation 68 ODT metoclopramide HCl PEPCID 68 Diabetic Macular Edema 68 Obese Teens 68 Hedgehog Pathway Inhibitor 68 Seasonal Allergies 68 Critically Ill Patients 68 Postmenopausal Osteoporosis 68 OTC BB PVCT 68 Novel Peptide 68 Romidepsin 68 platform HDL Mimetic 68 Spinal Fusion 68 Inflammatory Markers 68 ISSI Announces 68 LibiGel ® 68 Inflammatory Arthritis 68 Britney Spears Conservatorship 68 Diagnostic Tests 68 Trial Halted 68 Injection Site 68 Low Dose 68 Accelr8 Announces 68 Nasdaq XTLB 68 Civacir 68 Asthma COPD 68 Microplasmin 68 Shown Effective 68 Blocked Arteries 68 Kaydon Corporation Announces 68 Corneal Transplant 68 Cetrorelix 68 Secondary Hyperparathyroidism 68 Non Inferiority 68 Renal Function 68 Antipsychotic Drug 68 Circulating Tumor Cells 68 Announces Positive 68 Poorly Controlled 68 Regains NASDAQ 68 FUSILEV ® 68 Terminate Merger Agreement 68 Revises FY# EPS 68 R roscovitine CDK cyclin 68 evaluating picoplatin 68 Relapsed Refractory 68 Fentanyl Patch 68 Luveniq 68 Medicure Announces 68 Mln Share Buyback 68 Updates FY# EPS 68 Enzo Biochem Reports 68 Novel Therapeutic 68 Invoke Fifth Amendment 68 PDL BioPharma Announces 68 Winmark Corporation Announces 68 mGluR5 negative 68 Protein Linked 68 Endovascular Treatment 68 OxyContin Maker 68 CCX# B 68 Therapy Shows Promise 68 Nerve Pain 68 Study Validates 68 developing Bicifadine serotonin 68 Sirolimus Eluting 68 Genes Linked 68 Diet Pill 68 Often Misdiagnosed 68 Lifts FY# View 68 Boxed Warnings 68 Upcoming Milestones 68 non nucleoside inhibitor 68 Parathyroid Hormone 68 HemaCare Reports 68 Ovary Removal 68 Factor Xa Inhibitor 68 Cancer Vaccines 68 FelCor Announces 68 Pending Acquisition 68 Stock Buyback Plan 68 Zorbtive TM 68 Immune Cells 68 Malignant Melanoma 68 k Clearance 68 Levels Linked 68 Stent Thrombosis 68 Interferon Alpha 68 Stent Coating 68 Meet Primary Endpoint 68 Volume Shipments 68 Above Consensus 68 Gene Variants 68 Epratuzumab 68 Tentative Approval 68 Treat Anemia 68 Settle Patent Litigation 68 Fibromyalgia Pain 68 IDEXX Laboratories Announces 68 Androgen Deprivation Therapy 68 Receives Favorable 68 Announces Publication 68 TriMas Corporation Announces 68 Effective Than 68 Fourth Quarter Cash Dividend 68 Primary Efficacy Endpoint 68 Drug Eluting Stents 68 Pomerantz Law Firm 68 Medoro Resources Announces 68 Chronic Inflammation 68 Guidance Quick Facts 68 Valopicitabine 68 Novel Treatments 68 For Undisclosed Terms 68 Hematology Molecular Pathology 68 Panzem R 68 MKC# MT 68 Oral Presentations 68 SABER ™ 68 Liver Tumors 68 Drug Eluting Stent System 68 Milestone Achieved 68 Inflammatory Diseases 68 Auxilium Pharma 68 Keryx Biopharma 68 DARA logo 68 Improve Outcomes 68 GRAS Status 68 Drug Eluting 68 Post Operative 68 Therapeutic Potential 68 NICE Recommends 68 Device Maker 68 SinuNase TM 68 Advisers Urge 68 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 68 Pazopanib 68 Stent Placement 68 Marketing Authorisation Application 68 Rapid Expansion 68 Ischemic Stroke 68 Augment ™ 68 Amends Agreement 68 Initiated Phase 68 Invasive Fungal Infections 68 Tesamorelin 68 Syncria R 68 Oral Spray 68 investigational oral inhibitor 68 Oral Anticoagulant 68 Mg Uk 68 Hydrochlorothiazide Tablets 68 Premature Infants 68 Wizzard Software Announces 68 Q3 Profit Decreases 68 Transplant Patient 68 Mycophenolate Mofetil 68 MMR Vaccine 68 Q3 Loss Widens 68 Disease IBD 68 Total Knee Arthroplasty 68 TB Vaccine 68 Ovitrelle R Serostim 68 Rexahn Pharmaceuticals 68 Golimumab 68 Biologic Drugs 68 Nymox Reports 68 Surgical Procedures 68 Achieves Positive 68 microRNA Therapeutics 68 Hepatitis C Patients 68 Medullary Thyroid Cancer 68 Bush Embraces Pause 68 markets COLAZAL 68 Castration Resistant Prostate Cancer 68 Abiraterone Acetate 68 toenail onychomycosis 68 Pneumococcal Vaccine 68 Novel Antibody 68 Allergic Rhinitis 68 PROSTASCINT R 68 Atopic Dermatitis 68 Nasdaq Delisting 68 Proxy Proposals 68 NOTE POSIDUR ™ 68 Genetic Mutations 68 Bivalirudin 68 Invasive Breast Cancer 68 R Saizen R 68 Organ Rejection 68 Genetic Defect 68 oncolytic virus therapies 68 Pharma Merck Serono 68 Previously Announced Private Placement 68 Backs FY# Revenue 68 Sirolimus Eluting Stent 68 Cocaine Addiction 68 Clostridium difficile Infection